Q-omics provides the consensus-scored MED23 profile across patient tissues and cancer cell-line models. MED23 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MED23 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, MED23 protein abundance shows 32,364 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, THCA, and LSCC as cancer lineages where MED23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MED23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MED23 survival associations across molecular data types. MED23 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MED23 RNA expression–survival associations across cancer types. High MED23 expression shows unfavorable associations in LIHC, OV and MESO, but favorable associations in KIRC, READ and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for MED23 RNA expression.
This table summarizes MED23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 9. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MED23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MED23 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, BLCA, CHOL and STAD. The THCA box plot shows higher MED23 RNA expression in normal versus tumor tissue (log2 FC = −0.778, t-test p < 0.001).
This table shows molecular features associated with MED23 in patient tissues and cancer cell lines. In patient samples, MED23 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MED23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
